In the latest Health Policy Outlook, John E. Calfee makes the case for substantial social gains from preserving several years of data exclusivity for firms innovating new biotech drugs.

• Read this issue
• All Health Policy Outlooks
• AEI's Outlook series

To receive e-mail notifications when events or articles relating to your interests are posted on AEI.org, or simply to set up a personalized page on the website with these items, visit My AEI. Watch for specific

• scholars
• subject areas
• projects
• event series